Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by fox7mfon Dec 03, 2022 9:48am
422 Views
Post# 35148457

The pressure is on for Big Pharma...& Onc.

The pressure is on for Big Pharma...& Onc.A few of us have touched on how the Goblet results, the buzz around Aware results & the FDA FTD have all combined to rachet up the pressure on PFE, Roche & others to get Pela & Onc wrapped up. All true. Onc, however,  is not immune to the pressure to get a deal done. By deal done, I mean B/O. The huge importance of a timely purchase can't be underestimated. The value of Onc, at this time, might not get any higher. A partnership is ok, but wrinkles arise, problems come out of nowhere, and BP can end any partnership at the sign of the tiniest hiccup. If this were to happen,  everyone is left in the cold. Right now is the most oppurtune moment to sell, make off like bandits, and let BP get this to cancer patients. My opinion. 
<< Previous
Bullboard Posts
Next >>